Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Ta Yang

Showing results (151-160 of 310) with videos related to

Pageof 31
Sort By:
International Journal of Oncology|September 7, 2013
Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft modelMing-Szu Hung, Zhidong Xu, Yu Chen, et al.
Plos One|January 29, 2016
Long-Term Outcomes of Patients with Acute Cholecystitis after Successful Percutaneous Cholecystostomy Treatment and the Risk Factors for Recurrence: A Decade Experience at a Single CenterChih-Hung Wang, Cheng-Yi Wu, Justin Cheng-Ta Yang, et al.
American Journal of Translational Research|November 17, 2021
The effect of cullin 4A on lung cancer cell chemosensitivity to paclitaxel through p33ING1b regulationJrhau Lung, Yi-Chuan Chen, Yu-Ching Lin, et al.
Oncology Reports|June 25, 2019
Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine modelPing-Chih Hsu, Bo Tian, Yi-Lin Yang, et al.
Psychoneuroendocrinology|October 1, 2025
Relationships between childhood adversity, resilience, and inflammatory profiles in Taiwanese young adultsManuel Salvador Villa Jaimes, Siwahdol Chaimano, Sheng-Hsiang Lin, et al.
Thoracic Cancer|May 28, 2022
Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patientsJohn Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, et al.
Thoracic Cancer|November 25, 2022
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from TaiwanJohn Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, et al.
Therapeutic Advances in Respiratory Disease|October 28, 2022
Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutationsPing-Chih Hsu, John Wen-Cheng Chang, Ching-Fu Chang, et al.
Cancers|February 25, 2022
Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKIJohn Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, et al.
Thoracic Cancer|December 16, 2022
The survival after discontinuation of EGFR-TKIs due to intolerable adverse events in patients with EGFR-mutated non-small cell lung cancerJohn Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, et al.
Pageof 31

Showing results (151-160 of 310) with videos related to

Sort By:
Pageof 31
International Journal of Oncology|September 7, 2013
Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft modelMing-Szu Hung, Zhidong Xu, Yu Chen, et al.
Plos One|January 29, 2016
Long-Term Outcomes of Patients with Acute Cholecystitis after Successful Percutaneous Cholecystostomy Treatment and the Risk Factors for Recurrence: A Decade Experience at a Single CenterChih-Hung Wang, Cheng-Yi Wu, Justin Cheng-Ta Yang, et al.
American Journal of Translational Research|November 17, 2021
The effect of cullin 4A on lung cancer cell chemosensitivity to paclitaxel through p33ING1b regulationJrhau Lung, Yi-Chuan Chen, Yu-Ching Lin, et al.
Oncology Reports|June 25, 2019
Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine modelPing-Chih Hsu, Bo Tian, Yi-Lin Yang, et al.
Psychoneuroendocrinology|October 1, 2025
Relationships between childhood adversity, resilience, and inflammatory profiles in Taiwanese young adultsManuel Salvador Villa Jaimes, Siwahdol Chaimano, Sheng-Hsiang Lin, et al.
Thoracic Cancer|May 28, 2022
Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patientsJohn Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, et al.
Thoracic Cancer|November 25, 2022
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from TaiwanJohn Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, et al.
Therapeutic Advances in Respiratory Disease|October 28, 2022
Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutationsPing-Chih Hsu, John Wen-Cheng Chang, Ching-Fu Chang, et al.
Cancers|February 25, 2022
Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKIJohn Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, et al.
Thoracic Cancer|December 16, 2022
The survival after discontinuation of EGFR-TKIs due to intolerable adverse events in patients with EGFR-mutated non-small cell lung cancerJohn Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, et al.
Pageof 31